Biophytis S.A. (LON:0D1W)
0.0562
-0.0016 (-2.77%)
At close: Feb 11, 2026
Biophytis Employees
Biophytis had 19 employees as of December 31, 2024. The number of employees decreased by 3 or -13.64% compared to the previous year.
Employees
19
Change (1Y)
-3
Growth (1Y)
-13.64%
Revenue / Employee
n/a
Profits / Employee
-362.28K GBP
Market Cap
1.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 19 | -3 | -13.64% |
| Dec 31, 2023 | 22 | -2 | -8.33% |
| Dec 31, 2022 | 24 | -2 | -7.69% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | 4 | 19.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kanabo Group | 20 |
| Everest Global | 12 |
| Imaging Biometrics | 7 |
| Red Capital | 2 |
| R8 Capital Investments | 2 |
| Fragrant Prosperity Holdings | 1 |
Biophytis News
- 1 year ago - Biophytis unveils outlook strategies for 2025, to launch phase 3 of SARA clinical program - Seeking Alpha
- 1 year ago - Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities - Accesswire
- 1 year ago - Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia - Accesswire
- 1 year ago - Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity - Accesswire
- 1 year ago - Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris - Accesswire
- 1 year ago - Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million - Accesswire
- 1 year ago - Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities - Accesswire
- 1 year ago - Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens - Accesswire